Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Glepaglutide

Investigational

Long-acting GLP-2 analog

Also known as: ZP1848, Glepaglutide (USAN), ZP-1848, glepaglutida, glepaglutidum, ZP 1848

Evidence score

58/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 9 registered studies on ClinicalTrials.gov, most advanced Phase 3
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Glepaglutide is an investigational synthetic peptide designed to mimic glucagon-like peptide-2 (GLP-2), a gut hormone that supports the growth and absorptive function of the intestinal lining. It is engineered to last longer in the body than natural GLP-2 and has been studied mainly in people with short bowel syndrome, where it is thought to improve how the intestine absorbs fluids and nutrients.

What the evidence shows

Automatic summaryLimited human data

Glepaglutide is not FDA approved; it has been tested in 9 registered human trials reaching Phase 3, with about 31 published papers. Phase 3 results in short bowel syndrome suggest some reduction in the need for intravenous nutritional support, but the evidence is still under regulatory review and not considered conclusive.

Key facts

Molecular formula

C197H325N53O55

Molecular weight

4316 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

9registered studies

Phase 3most advanced phase

7completed (sample)

1recruiting (sample)

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Phase 3RecruitingNCT07197944

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

Phase 3CompletedNCT03905707

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

Phase 3CompletedNCT03690206

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

Phase 1CompletedNCT04178447

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

32papers referencing Glepaglutide

Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.

Lancet Gastroenterol Hepatol2019

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.

J Pharmacol Exp Ther2020

Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial.

JPEN J Parenter Enteral Nutr2020

Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial.

EBioMedicine2019

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.